3D laparoscopic prostatectomy: results of multicentre study.


Journal

Scandinavian journal of urology
ISSN: 2168-1813
Titre abrégé: Scand J Urol
Pays: Sweden
ID NLM: 101587186

Informations de publication

Date de publication:
Jun 2022
Historique:
pubmed: 1 6 2022
medline: 1 7 2022
entrez: 31 5 2022
Statut: ppublish

Résumé

Three-dimensional laparoscopic prostatectomy (3D LRP) is a potentially cost-effective option for robot-assisted laparoscopic prostatectomy (RALP). Results for two-dimensional LRP and RALP are well documented; however, little has been published on the outcomes of 3D LRP. Our objective was to report the perioperative and short-term results of 3D LRP in a multicentre study. In total, 496 unselected men with prostate cancer underwent 3D LRP by three surgeons between December 2013 and December 2018. Median age was 64 (43-76) years. Median prostate-specific antigen (PSA) was 7.9 (0.7-148) ng/ml. Preoperative and perioperative data and complications according to the Clavien-Dindo classification were collected. PSA and continence results were reported at 3 and 12 months postoperatively. Data were analysed with IBM SPSS statistics (25). Pathological Gleason score was 6 in 29%, 7 in 55.4%, 8 in 9.1%, 9 in 5.2% and 10 in 1.2% of patients. Pathological tumour classification was T2c in 59.5%, T3a in 19.5% and T3b in 10.9% of cases. Positive surgical margins occurred in 27.2%. Lymphadenectomy was performed in 36.3%, with positive lymph nodes in 11.8%. Median operative time was 137 (78-334) min and median blood loss 200 (10-1100) ml. Clavien-Dindo IIIa and IIIb complications occurred in 6.9% and 1.6%, respectively. At 3 and 12 months postoperatively, 90.2% and 91.4% of patients, respectively, had PSA <0.2 ng/ml, while 77.1% and 87.7% of patients were completely dry or using a maximum of one pad daily. 3D LRP shows promising results, comparable to similar studies published on RALP.

Identifiants

pubmed: 35634887
doi: 10.1080/21681805.2022.2075458
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

176-181

Auteurs

Henry Haapiainen (H)

Department of Urology, The Hospital District of South Ostrobothnia, Seinäjoki, Finland.

Antti Kaipia (A)

Department of Urology, TAYS Cancer Centre, Tampere, Finland.

Teemu Murtola (T)

Department of Urology, TAYS Cancer Centre, Tampere, Finland.
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Heikki Seikkula (H)

Department of Urology, Central Finland Health Care District, Jyväskylä, Finland.

Marjo Seppänen (M)

Department of Urology, Satakunta Hospital District, Pori, Finland.

Pyry Jämsä (P)

Department of Urology, TAYS Cancer Centre, Tampere, Finland.

Mika Raitanen (M)

Department of Urology, The Hospital District of South Ostrobothnia, Seinäjoki, Finland.
Department of Urology, TAYS Cancer Centre, Tampere, Finland.
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH